Related Experiment Video
Updated: Mar 11, 2026

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy
Published on: December 30, 2025
Circulating microRNA levels predict residual beta cell function and glycaemic control in children with type 1
Nasim Samandari1, Aashiq H Mirza1,2, Lotte B Nielsen1
1Copenhagen Diabetes Research Center (CPH-DIRECT), Department of Paediatrics, Herlev and Gentofte Hospitals, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark.
Insights
Circulating microRNAs (miRNAs) can predict type 1 diabetes progression. Specifically, hsa-miR-197-3p at 3 months post-diagnosis is a strong indicator of beta cell function one year later in children.
Area of Science:
- Endocrinology
- Molecular Biology
- Genetics
Background:
- Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by the destruction of pancreatic beta cells.
- Predicting clinical progression and residual beta cell function in new-onset T1DM is crucial for personalized treatment strategies.
- MicroRNAs (miRNAs) are small non-coding RNAs that play regulatory roles in various biological processes, including beta cell function and immune responses.
Purpose of the Study:
- To identify circulating miRNAs that predict clinical progression in children with new-onset type 1 diabetes mellitus.
- To evaluate the predictive value of specific miRNAs for residual beta cell function and glycemic control.
- To validate identified miRNA biomarkers in a larger cohort.
Main Methods:
- Prospective collection of plasma samples from 123 children with new-onset T1DM at multiple time points post-diagnosis.
- miRNA profiling of plasma samples from a subset of 40 children.
- Measurement of meal-stimulated C-peptide and HbA1c levels, with calculation of insulin-dose adjusted HbA1c (IDAA1c).
- Validation of candidate miRNAs in the remaining cohort (n=83) using multiple linear regression analysis.
Main Results:
- Six miRNAs (hsa-miR-24-3p, hsa-miR-146a-5p, hsa-miR-194-5p, hsa-miR-197-3p, hsa-miR-301a-3p, hsa-miR-375) at 3 months correlated with residual beta cell function at 6-12 months.
- hsa-miR-197-3p at 3 months significantly predicted stimulated C-peptide at 12 months (p=0.034).
- hsa-miR-24-3p and hsa-miR-146a-5p at 3 months predicted lower IDAA1c at 12 months (p<0.014 and p<0.022, respectively).
- The predictive value of hsa-miR-197-3p was confirmed in the validation cohort (p=0.018).
Conclusions:
- The miRNA hsa-miR-197-3p, detected 3 months after diagnosis, is a strong predictor of residual beta cell function one year later in children with T1DM.
- Circulating miRNAs, particularly hsa-miR-197-3p, hold potential as non-invasive biomarkers for predicting T1DM progression and guiding therapeutic interventions.
- Further research into the target genes of these miRNAs may elucidate pathways involved in T1DM pathogenesis, including those related to the gonadotropin-releasing hormone receptor and angiogenesis.
Aims/Hypothesis:
We aimed to identify circulating microRNA (miRNA) that predicts clinical progression in a cohort of 123 children with new-onset type 1 diabetes mellitus.
Methods:
Plasma samples were prospectively obtained at 1, 3, 6, 12 and 60 months after diagnosis from a subset of 40 children from the Danish Remission Phase Cohort, and profiled for miRNAs. At the same time points, meal-stimulated C-peptide and HbA1c levels were measured and insulin-dose adjusted HbA1c (IDAA1c) calculated. miRNAs that at 3 months after diagnosis predicted residual beta cell function and glycaemic control in this subgroup were further validated in the remaining cohort (n = 83). Statistical analysis of miRNA prediction for disease progression was performed by multiple linear regression analysis adjusted for age and sex.
Results:
In the discovery analysis, six miRNAs (hsa-miR-24-3p, hsa-miR-146a-5p, hsa-miR-194-5p, hsa-miR-197-3p, hsa-miR-301a-3p and hsa-miR-375) at 3 months correlated with residual beta cell function 6-12 months after diagnosis. Stimulated C-peptide at 12 months was predicted by hsa-miR-197-3p at 3 months (p = 0.034). A doubling of this miRNA level corresponded to a sixfold higher stimulated C-peptide level. In addition, a doubling of hsa-miR-24-3p and hsa-miR-146a-5p levels at 3 months corresponded to a 4.2% (p < 0.014) and 3.5% (p < 0.022) lower IDAA1c value at 12 months. Analysis of the remaining cohort confirmed the initial finding for hsa-miR-197-3p (p = 0.018). The target genes for the six miRNAs revealed significant enrichment for pathways related to gonadotropin-releasing hormone receptor and angiogenesis pathways.
Conclusions/Interpretation:
The miRNA hsa-miR-197-3p at 3 months was the strongest predictor of residual beta cell function 1 year after diagnosis in children with type 1 diabetes mellitus.
More Related Videos
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...

